E
Description
Biopharmaceutical company founded in 2016 in Durham, NC. Develops Norketotifen to treat long COVID and influenza-like illnesses. Focused on reducing release of inflammatory cytokines from mast cells (hypercytokinemia). Backed by Hatteras Venture Partners and others. Raised $16.6M.